CHMA Key Statistics, Chart & Performance
The current stock price of CHMA is 3.76 null. In the past month the price decreased by -13.56%. In the past year, price decreased by -21.5%.
CHMA Technical Analysis
CHMA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CHMA. While CHMA seems to be doing ok healthwise, there are quite some concerns on its profitability.
CHMA Financial Highlights
Over the last trailing twelve months CHMA reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS decreased by -46.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -2968.35% | ||
| ROA | -56.38% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CHMA Forecast & Estimates
4 analysts have analysed CHMA and the average price target is 9.28 null. This implies a price increase of 146.86% is expected in the next year compared to the current price of 3.76.
For the next year, analysts expect an EPS growth of 12.13% and a revenue growth 1731.35% for CHMA
CHMA Ownership
CHMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.86 | 974.18B | ||
| JNJ | JOHNSON & JOHNSON | 21.14 | 528.77B | ||
| MRK | MERCK & CO. INC. | 12.65 | 276.67B | ||
| PFE | PFIZER INC | 8.08 | 146.98B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.61 | 115.03B | ||
| ZTS | ZOETIS INC | 19.8 | 55.33B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.65 | 22.90B | ||
| VTRS | VIATRIS INC | 5.51 | 14.78B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.41 | 12.12B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.75B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.31B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.32B |
Related stock screener links
About CHMA
Company Profile
Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. The company is headquartered in Needham, Massachusetts and currently employs 85 full-time employees. The company went IPO on 2015-07-16. The firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The firm has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The firm is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The firm's TPE technology enhances the absorption through the intestinal wall of drugs. The firm also focuses on developing CH2 for Orphan indication.
Company Info
Chiasma Inc
140 Kendrick Street, Building C East
Needham MASSACHUSETTS 02494 US
CEO: Raj Kannan
Employees: 85
Phone: 16179285300.0
Chiasma Inc / CHMA FAQ
What does Chiasma Inc do?
Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. The company is headquartered in Needham, Massachusetts and currently employs 85 full-time employees. The company went IPO on 2015-07-16. The firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The firm has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The firm is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The firm's TPE technology enhances the absorption through the intestinal wall of drugs. The firm also focuses on developing CH2 for Orphan indication.
Can you provide the latest stock price for Chiasma Inc?
The current stock price of CHMA is 3.76 null. The price decreased by -6% in the last trading session.
What is the dividend status of Chiasma Inc?
CHMA does not pay a dividend.
What is the ChartMill technical and fundamental rating of CHMA stock?
CHMA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for CHMA stock?
4 analysts have analysed CHMA and the average price target is 9.28 null. This implies a price increase of 146.86% is expected in the next year compared to the current price of 3.76.
Would investing in Chiasma Inc be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CHMA.